BIOVENTUS INC ($NASDAQ:BVS) announced their second quarter earnings results for FY2023 on August 8 2023, revealing a total revenue of USD 137.1 million, a 2.3% decrease from the same quarter in the previous year. Net income for the quarter was significantly improved compared to the prior year, reaching USD -3.7 million compared to the prior year’s figure of -7.2 million.
GoodWhale has conducted a wellbeing analysis on BIOVENTUS INC and determined that it is a high risk investment based on its Risk Rating. GoodWhale has identified 3 risk warnings in the company’s income sheet, balance sheet, and cashflow statement, which are only accessible to registered users. This is an indication that the company may be facing some financial challenges and potential risks that investors should be aware of. BIOVENTUS INC has generated some revenue over the past few years, however, due to market changes, there may be a decrease in the business and financial sustainability of this company. It is important for investors to consider the risks associated with investing in BIOVENTUS INC and understand the potential financial implications of doing so. GoodWhale’s analysis provides relevant information to make an informed decision about investing in this company. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Bioventus Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bioventus Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bioventus Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Bioventus Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The market for bioventus is highly competitive with Motus GI Holdings Inc, Lucid Diagnostics Inc, Reshape Lifesciences Inc, all vying for a share of the pie. Bioventus Inc has a strong product portfolio and is well-positioned to compete in this market.
– Motus GI Holdings Inc ($NASDAQ:MOTS)
Motus GI Holdings Inc is a medical technology company that focuses on the development of endoscopic devices to provide gastrointestinal access and improve clinical outcomes. The company’s market cap as of 2022 is 5.93M and its ROE is -183.03%. Motus GI’s products are designed to provide superior clinical outcomes and improve patient safety by reducing procedural time, minimizing tissue trauma, and enhancing endoscopic visualization.
– Lucid Diagnostics Inc ($NASDAQ:LUCD)
Lucid Diagnostics Inc is a medical diagnostic company that develops and commercializes technology for the early detection of life-threatening diseases. The company’s products are based on the principle of detecting the presence of disease-specific antibodies in a patient’s blood. Lucid’s products are designed to provide accurate and reliable results within minutes, and are intended for use by both healthcare professionals and consumers. Lucid has a market cap of 71.74M as of 2022, a Return on Equity of -67.45%. The company’s products are based on the principle of detecting the presence of disease-specific antibodies in a patient’s blood. Lucid’s products are designed to provide accurate and reliable results within minutes, and are intended for use by both healthcare professionals and consumers.
– Reshape Lifesciences Inc ($NASDAQ:RSLS)
Reshape Lifesciences Inc is a biotechnology company that focuses on the development of therapies for the treatment of obesity and related diseases. The company has a market cap of 6.99M as of 2022 and a return on equity of -124.4%. Reshape Lifesciences Inc is headquartered in San Diego, California.
Investors have been cautiously optimistic over the second quarter earnings results of BIOVENTUS INC for FY2023, which saw total revenue decline by 2.3%. However, the net income of -3.7 million was an improvement from the prior year’s figure. This suggests that BIOVENTUS INC has been able to mitigate the negative impacts of the pandemic and is on its way to recovery. Going forward, investors may be willing to invest in this company as long as it continues to show progress in its financial performance.